

Marlies S Wijsenbeek

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4563191/marlies-s-wijsenbeek-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97
papers

2,189
citations

27
h-index

43
g-index

114
ext. papers

3,585
ext. citations

9.6
avg, IF

5.41
L-index

#	Paper	IF	Citations
97	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. <i>European Respiratory Journal</i> , 2014 , 44, 1296-307	13.6	126
96	Palliative care in interstitial lung disease: living well. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 968-980	35.1	115
95	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 1036-1044	10.2	109
94	Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 2299-2307	27.4	107
93	Spectrum of Fibrotic Lung Diseases. <i>New England Journal of Medicine</i> , 2020 , 383, 958-968	59.2	102
92	European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. <i>European Respiratory Journal</i> , 2016 , 47, 597-606	13.6	71
91	A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 806-815	35.1	71
90	Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. <i>Current Medical Research and Opinion</i> , 2019 , 35, 2015-2024	2.5	65
89	Cough in idiopathic pulmonary fibrosis. <i>European Respiratory Review</i> , 2016 , 25, 278-86	9.8	62
88	Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. <i>European Respiratory Journal</i> , 2016 , 47, 889-97	13.6	54
87	Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	53
86	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). <i>BMJ Open Respiratory Research</i> , 2019 , 6, e000422	5.6	50
85	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	50
84	Optimizing quality of life in patients with idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , 2017 , 11, 157-169	4.9	49
83	Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	48
82	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. <i>BioMed Research International</i> , 2015 , 2015, 329481	3	44
81	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2016 , 47, 1776-84	13.6	43

80	Treatment of Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015 , 36, 751-67	5.3	42
79	Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 657-664	35.1	42
78	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022 , 205, e18-e47	10.2	38
77	Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	37
76	Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 1349-1379	5.8	34
75	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 1146-1153	10.2	33
74	Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease. <i>Respiration</i> , 2020 , 99, 73-82	3.7	30
73	The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	30
72	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2018 , 95, 317-326	3.7	29
71	Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 393-401	10.2	28
70	Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. <i>Respiration</i> , 2018 , 96, 514-524	3.7	27
69	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. <i>Respiration</i> , 2019 , 97, 173-184	3.7	27
68	No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. <i>Respiratory Medicine</i> , 2018 , 138S, S31-S37	4.6	27
67	Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 152-159	10.2	25
66	Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis. <i>Advances in Therapy</i> , 2015 , 32, 691-704	4.1	24
65	Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	24
64	Th17-lineage cells in pulmonary sarcoidosis and Löfgren's syndrome: Friend or foe?. <i>Journal of Autoimmunity</i> , 2018 , 87, 82-96	15.5	22
63	What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany. <i>ERJ Open Research</i> , 2017 , 3,	3.5	20

62	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	18
61	Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis. <i>Frontiers in Medicine</i> , 2017 , 4, 226	4.9	18
60	Medical Therapy in Idiopathic Pulmonary Fibrosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016 , 37, 368-77	3.9	17
59	Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. <i>ERJ Open Research</i> , 2019 , 5,	3.5	17
58	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. <i>European Respiratory Journal</i> , 2016 , 48, 1524-1526	13.6	16
57	Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	16
56	Desquamative interstitial pneumonia: a systematic review of its features and outcomes. <i>European Respiratory Review</i> , 2020 , 29,	9.8	15
55	New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises?. <i>Current Opinion in Pulmonary Medicine</i> , 2016 , 22, 434-41	3	15
54	Patient and partner empowerment programme for idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	14
53	Feasibility of a Comprehensive Home Monitoring Program for Sarcoidosis. <i>Journal of Personalized Medicine</i> , 2019 , 9,	3.6	14
52	Comprehensive Care for Patients with Sarcoidosis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	14
51	Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS trials. <i>Respiratory Research</i> , 2020 , 21, 36	7.3	13
50	Cultural Differences in Palliative Care in Patients With Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2015 , 148, e56	5.3	13
49	The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. <i>Respiratory Research</i> , 2020 , 21, 197	7.3	13
48	Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). <i>Patient</i> , 2017 , 10, 629-642	3.7	12
47	Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2019 , 20, 232	7.3	11
46	Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. <i>Respiratory Research</i> , 2021 , 22, 84	7.3	11
45	Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. <i>Chronic Respiratory Disease</i> , 2017 , 14, 140-150	3	10

44	Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2020 , 21, 312	7.3	10
43	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. <i>Advances in Therapy</i> , 2019 , 36, 232-243	4.1	9
42	Development and feasibility of an eHealth tool for idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	9
41	First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. <i>BMJ Open Respiratory Research</i> , 2019 , 6, e000394	5.6	9
40	Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. <i>Patient</i> , 2019 , 12, 149-162	3.7	8
39	Acetylcysteine in IPF: the knockout blow?. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 420-1	35.1	7
38	Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 271	3.5	7
37	Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	7
36	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1065-1076	35.1	7
35	Managing Fatigue in Patients With Interstitial Lung Disease. <i>Chest</i> , 2020 , 158, 2026-2033	5.3	6
34	The impact of the new Global Lung Function Initiative reference values on trial inclusion for patients with idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	5
33	Progress in the treatment of pulmonary fibrosis. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 424-425	35.1	5
32	Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. <i>ERJ Open Research</i> , 2020 , 6,	3.5	5
31	Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. <i>Respiratory Research</i> , 2020 , 21, 196	7.3	5
30	Educational aspects of rare and orphan lung diseases. <i>Respiratory Research</i> , 2021 , 22, 92	7.3	5
29	European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity. <i>European Respiratory Journal</i> , 2016 , 48, 283-4	13.6	4
28	Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. <i>ERJ Open Research</i> , 2019 , 5,	3.5	4
27	Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials. <i>Respiratory Medicine</i> , 2019 , 150, 120-125	4.6	2

26	The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 192-202	1.1	2
25	Evaluation of a Home Monitoring Application for Follow Up after Lung Transplantation-A Pilot Study. <i>Journal of Personalized Medicine</i> , 2020 , 10,	3.6	2
24	Gender equity in interstitial lung disease. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 842-843	35.1	2
23	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. <i>European Respiratory Review</i> , 2021 , 30,	9.8	2
22	Management of Idiopathic Pulmonary Fibrosis. <i>Clinics in Chest Medicine</i> , 2021 , 42, 275-285	5.3	2
21	Research highlights from the 2018 ERS International Congress: interstitial lung diseases. <i>ERJ Open Research</i> , 2019 , 5,	3.5	2
20	Cough, an unresolved problem in interstitial lung diseases. <i>Current Opinion in Supportive and Palliative Care</i> , 2019 , 13, 143-151	2.6	2
19	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	2
18	The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry.. <i>Respiratory Medicine</i> , 2022 , 196, 106801	4.6	2
17	Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.. <i>Annals of the American Thoracic Society</i> , 2022 , 19, 833-844	4.7	2
16	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. <i>Advances in Therapy</i> , 2019 , 36, 3059-3070	4.1	1
15	COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes. <i>Current Opinion in Pulmonary Medicine</i> , 2021 , 27, 463-471	3	1
14	Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study. <i>Rheumatology</i> , 2021 , 60, 2467-2471	3.9	1
13	Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population. <i>Chronic Respiratory Disease</i> , 2021 , 18, 14799731211031935	3	1
12	The Value of the Surprise Question to Predict One-Year Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study. <i>Respiration</i> , 2021 , 100, 780-785	3.7	1
11	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, e3-e23	10.2	1
10	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. <i>Advances in Therapy</i> , 2021 , 38, 4040-4056	4.1	0
9	The use of online visual analogue scales in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2021 ,	13.6	0

8	Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey. <i>Frontiers in Medicine</i> , 2021 , 8, 711194	4.9	○
7	PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough.. <i>Trials</i> , 2022 , 23, 184	2.8	○
6	Trafficking and lysosomal storage disorders 2019 , 319-332		
5	Comprehensive Care of Interstitial Lung Disease 2022 , 64-78		
4	Palliative Care in Interstitial Lung Disease. <i>Respiratory Medicine</i> , 2021 , 189-207	0.2	
3	Challenges in the classification of fibrotic ILD: Patient case 2. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2015 , 32 Suppl 1, 13-6	1.1	
2	Non-organ-specific manifestations of sarcoidosis 2022 , 206-222		
1	Comparison of the treatment guidelines for sarcoidosis: common sense in the search for evidence.. <i>European Respiratory Journal</i> , 2021 ,	13.6	